×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Nurix Therapeutics Inc. (NRIX) NASDAQ

$15.90 0.95 (6.35%)

Market Cap: $734.80M

As of 05/15/24 04:00 PM EDT. Market closed.

(NRIX)

Nurix Therapeutics Inc. (NRIX)
NASDAQ

$15.90
0.95 (6.35%)

Market Cap: $734.80M

As of 05/15/24 04:00 PM EDT. Market closed.

Add to Portfolio

nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – ... read more

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
300
Address
.
PRICE CHART FOR NURIX THERAPEUTICS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$15.83
Previous Close
$14.95
Days Range
$15.41 - $16.57
52 week range
$4.22 - $18.12
Volume
979,161
Avg. Volume (30 days)
933,682
Market Cap
$734.80M
Dividend Yield
-
P/E
(5.08)
Shares Outstanding
49,150,794
Open
$15.83
Previous Close
$14.95
Days Range
$15.41 - $16.57
52 week range
$4.22 - $18.12
Volume
979,161
Avg. Volume (30 days)
933,682
Market Cap
$734.80M
Dividend Yield
-
P/E
(5.08)
Shares Outstanding
49,150,794
FINANCIAL STATEMENTS FOR NURIX THERAPEUTICS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR NURIX THERAPEUTICS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
van Houte HansChief Financial OfficerMay 02, 2024 Sale$12.833,49944,87868,333May 02, 2024, 06:01 PM
van Houte HansChief Financial OfficerApr 30, 2024 Sale$12.041,38716,70371,832Apr 30, 2024, 06:33 PM
Hansen GwennChief Scientific OfficerApr 30, 2024 Sale$12.042,00724,16939,601Apr 30, 2024, 06:33 PM
Ring ChristineChief Legal OfficerApr 30, 2024 Sale$12.041,51318,22019,838Apr 30, 2024, 06:33 PM
van Houte HansChief Financial OfficerFeb 16, 2024 Sale$10.026,81268,22368,333Feb 16, 2024, 07:20 PM
van Houte HansChief Financial OfficerJan 30, 2024 Sale$7.991,67113,35275,145Jan 30, 2024, 06:53 PM
Hansen GwennChief Scientific OfficerJan 30, 2024 Sale$7.992,33418,64936,402Jan 30, 2024, 06:52 PM
Ring ChristineChief Legal OfficerJan 30, 2024 Sale$7.991,76014,06317,427Jan 30, 2024, 06:52 PM
van Houte HansChief Financial OfficerDec 20, 2023 Sale$10.003,54135,42171,930Dec 21, 2023, 05:19 PM
van Houte HansChief Financial OfficerDec 19, 2023 Sale$10.0010,906109,09375,471Dec 20, 2023, 04:55 PM
van Houte HansChief Financial OfficerOct 31, 2023 Sale$5.201,0805,61386,377Nov 01, 2023, 04:41 PM
Ring ChristineChief Legal OfficerOct 31, 2023 Sale$5.201,2326,40315,263Nov 01, 2023, 04:40 PM
Hansen GwennChief Scientific OfficerOct 31, 2023 Sale$5.201,6338,48733,529Nov 01, 2023, 04:40 PM
van Houte HansChief Financial OfficerJul 31, 2023 Sale$9.651,24512,02082,571Aug 01, 2023, 04:28 PM
Ring ChristineGeneral CounselJul 31, 2023 Sale$9.651,42013,71012,544Aug 01, 2023, 04:27 PM
Hansen GwennChief Scientific OfficerJul 31, 2023 Sale$9.651,88418,18929,955Aug 01, 2023, 04:26 PM
Wolff StefaniEVP and COOMay 01, 2023 Sale$9.883423,3786,113May 02, 2023, 04:33 PM
van Houte HansChief Financial OfficerMay 01, 2023 Sale$9.887217,12178,930May 02, 2023, 04:33 PM
Ring ChristineGeneral CounselMay 01, 2023 Sale$9.886826,73610,040May 02, 2023, 04:32 PM
Hansen GwennChief Scientific OfficerMay 01, 2023 Sale$9.881,13611,21926,632May 02, 2023, 04:31 PM
Wolff StefaniEVP and COOJan 30, 2023 Sale$11.784244,9953,940Feb 01, 2023, 04:18 PM
van Houte HansChief Financial OfficerJan 30, 2023 Sale$11.7892410,88476,765Feb 01, 2023, 04:17 PM
Ring ChristineGeneral CounselJan 30, 2023 Sale$11.788489,9897,261Feb 01, 2023, 04:16 PM
Hansen GwennChief Scientific OfficerJan 30, 2023 Sale$11.781,41216,63323,009Feb 01, 2023, 04:15 PM
van Houte HansChief Financial OfficerOct 31, 2022 Sale$12.887399,51974,803Nov 01, 2022, 07:35 PM
Ring ChristineGeneral CounselOct 31, 2022 Sale$12.886999,0036,185Nov 01, 2022, 07:34 PM
Hansen GwennChief Scientific OfficerOct 31, 2022 Sale$12.881,16515,00621,214Nov 01, 2022, 07:33 PM
Wolff StefaniEVP and COOOct 31, 2022 Sale$12.883504,5083,402Nov 01, 2022, 07:32 PM
Ring ChristineGeneral CounselAug 01, 2022 Sale$15.6771211,1574,615Aug 02, 2022, 05:50 PM
Wolff StefaniEVP and COOAug 01, 2022 Sale$15.673565,5791,238Aug 02, 2022, 05:48 PM
van Houte HansChief Financial OfficerAug 01, 2022 Sale$15.6775211,78472,656Aug 02, 2022, 05:46 PM
Hansen GwennChief Scientific OfficerAug 01, 2022 Sale$15.671,18618,58519,172Aug 02, 2022, 05:45 PM
van Houte HansChief Financial OfficerMay 31, 2022 Option Exercise$0.8468,33357,40070,522Jun 01, 2022, 04:57 PM
Hansen GwennChief Scientific OfficerMay 02, 2022 Sale$11.751,09812,90217,151May 03, 2022, 07:05 PM
Wolff StefaniEVP and COOMay 02, 2022 Sale$11.753303,878632May 03, 2022, 07:04 PM
van Houte HansChief Financial OfficerMay 02, 2022 Sale$11.756978,1902,189May 03, 2022, 07:03 PM
Ring ChristineGeneral CounselMay 02, 2022 Sale$11.756607,7553,403May 03, 2022, 07:03 PM
Ring ChristineGeneral CounselJan 10, 2022 Option Exercise$1.861,2002,2322,486Jan 11, 2022, 04:10 PM
Ring ChristineGeneral CounselJan 10, 2022 Sale$27.141,20032,5681,286Jan 11, 2022, 04:10 PM
Ring ChristineGeneral CounselDec 10, 2021 Option Exercise$1.861,2002,2322,486Dec 13, 2021, 04:47 PM
Ring ChristineGeneral CounselDec 10, 2021 Sale$29.041,20034,8481,286Dec 13, 2021, 04:47 PM
Hansen GwennChief Scientific OfficerDec 01, 2021 Option Exercise$7.264002,90414,597Dec 02, 2021, 05:43 PM
Hansen GwennChief Scientific OfficerDec 01, 2021 Sale$29.1340011,65214,197Dec 02, 2021, 05:43 PM
Ring ChristineGeneral CounselNov 10, 2021 Option Exercise$1.861,2002,2322,486Nov 12, 2021, 05:15 PM
Ring ChristineGeneral CounselNov 10, 2021 Sale$32.381,20038,8561,286Nov 12, 2021, 05:15 PM
Hansen GwennChief Scientific OfficerNov 01, 2021 Option Exercise$7.264002,90414,597Nov 02, 2021, 05:28 PM
Hansen GwennChief Scientific OfficerNov 01, 2021 Sale$33.2440013,29614,197Nov 02, 2021, 05:28 PM
Ring ChristineGeneral CounselOct 27, 2021 Option Exercise$1.868001,4882,086Oct 28, 2021, 07:25 PM
Ring ChristineGeneral CounselOct 27, 2021 Sale$35.2580028,2001,286Oct 28, 2021, 07:25 PM
Hansen GwennChief Scientific OfficerOct 27, 2021 Option Exercise$7.264002,90414,597Oct 28, 2021, 07:23 PM
Hansen GwennChief Scientific OfficerOct 27, 2021 Sale$35.0040014,00014,197Oct 28, 2021, 07:23 PM
Ring ChristineGeneral CounselOct 11, 2021 Option Exercise$1.861,2002,2322,486Oct 12, 2021, 06:43 PM
Ring ChristineGeneral CounselOct 11, 2021 Sale$27.361,20032,8321,286Oct 12, 2021, 06:43 PM
Hansen GwennChief Scientific OfficerOct 01, 2021 Option Exercise$7.264002,90414,597Oct 04, 2021, 05:16 PM
Hansen GwennChief Scientific OfficerOct 01, 2021 Sale$29.9240011,96814,197Oct 04, 2021, 05:16 PM
Ring ChristineGeneral CounselSep 10, 2021 Option Exercise$1.862,0003,7203,286Sep 13, 2021, 04:07 PM
Ring ChristineGeneral CounselSep 10, 2021 Sale$35.932,00071,8602,586Sep 13, 2021, 04:07 PM
Ring ChristineGeneral CounselSep 07, 2021 Option Exercise$1.863,2005,9524,486Sep 08, 2021, 05:08 PM
Ring ChristineGeneral CounselSep 07, 2021 Sale$35.253,200112,8001,286Sep 08, 2021, 05:08 PM
Hansen GwennChief Scientific OfficerSep 07, 2021 Option Exercise$7.261,60011,61615,797Sep 08, 2021, 05:08 PM
Hansen GwennChief Scientific OfficerSep 07, 2021 Sale$35.001,60056,00014,197Sep 08, 2021, 05:08 PM
Hansen GwennChief Scientific OfficerSep 01, 2021 Option Exercise$7.264002,90414,597Sep 02, 2021, 04:22 PM
Hansen GwennChief Scientific OfficerSep 01, 2021 Sale$32.3440012,93614,197Sep 02, 2021, 04:22 PM
Ring ChristineGeneral CounselAug 10, 2021 Option Exercise$1.861,2002,2322,005Aug 11, 2021, 06:21 PM
Ring ChristineGeneral CounselAug 10, 2021 Sale$29.871,20035,845805Aug 11, 2021, 06:21 PM
Beaurang PierreChief Business OfficerAug 10, 2021 Option Exercise$1.117,5008,32511,830Aug 11, 2021, 06:20 PM
Beaurang PierreChief Business OfficerAug 10, 2021 Sale$29.867,500223,9266,210Aug 11, 2021, 06:20 PM
Hansen GwennChief Scientific OfficerAug 02, 2021 Option Exercise$7.264002,90414,204Aug 03, 2021, 05:39 PM
Hansen GwennChief Scientific OfficerAug 02, 2021 Sale$31.2140012,48413,804Aug 03, 2021, 05:39 PM
Ring ChristineGeneral CounselJul 20, 2021 Option Exercise$1.861,2002,2322,005Jul 21, 2021, 05:34 PM
Ring ChristineGeneral CounselJul 20, 2021 Sale$27.001,20032,400805Jul 21, 2021, 05:34 PM
Beaurang PierreChief Business OfficerJul 12, 2021 Option Exercise$1.117,5008,32511,830Jul 12, 2021, 07:36 PM
Beaurang PierreChief Business OfficerJul 12, 2021 Sale$23.927,500179,4194,730Jul 12, 2021, 07:36 PM
Hansen GwennChief Scientific OfficerJul 01, 2021 Option Exercise$7.264002,90414,204Jul 02, 2021, 04:03 PM
Hansen GwennChief Scientific OfficerJul 01, 2021 Sale$26.7640010,70413,804Jul 02, 2021, 04:03 PM
Ring ChristineGeneral CounselMay 10, 2021 Option Exercise$1.861,2002,2322,005May 11, 2021, 07:58 PM
Ring ChristineGeneral CounselMay 10, 2021 Sale$27.001,20032,400805May 11, 2021, 07:58 PM
Ring ChristineGeneral CounselApr 28, 2021 Option Exercise$1.868001,4881,605Apr 29, 2021, 06:05 PM
Ring ChristineGeneral CounselApr 28, 2021 Sale$35.2580028,200805Apr 29, 2021, 06:05 PM
Ring ChristineGeneral CounselApr 12, 2021 Option Exercise$1.861,2002,2322,005Apr 13, 2021, 05:20 PM
Ring ChristineGeneral CounselApr 12, 2021 Sale$27.201,20032,640805Apr 13, 2021, 05:20 PM
Beaurang PierreChief Business OfficerApr 12, 2021 Option Exercise$1.027,5007,67811,830Apr 13, 2021, 05:19 PM
Beaurang PierreChief Business OfficerApr 12, 2021 Sale$27.287,500204,6327,758Apr 13, 2021, 05:19 PM
Beaurang PierreChief Business OfficerMar 25, 2021 Option Exercise$0.844,3303,6374,330Mar 25, 2021, 07:23 PM
Hansen GwennChief Scientific OfficerMar 16, 2021 Option Exercise$7.268005,80814,604Mar 16, 2021, 06:50 PM
Hansen GwennChief Scientific OfficerMar 16, 2021 Sale$45.0080036,00013,804Mar 16, 2021, 06:50 PM
Ring ChristineGeneral CounselMar 10, 2021 Option Exercise$1.862,0003,7202,805Mar 11, 2021, 05:35 PM
Ring ChristineGeneral CounselMar 10, 2021 Sale$41.272,00082,5391,905Mar 11, 2021, 05:35 PM
Beaurang PierreChief Business OfficerMar 08, 2021 Option Exercise$0.847,5006,3007,500Mar 09, 2021, 04:04 PM
Beaurang PierreChief Business OfficerMar 08, 2021 Sale$37.027,500277,6784,690Mar 09, 2021, 04:04 PM
Hansen GwennChief Scientific OfficerMar 01, 2021 Option Exercise$7.268005,80814,604Mar 02, 2021, 05:29 PM
Hansen GwennChief Scientific OfficerMar 01, 2021 Sale$35.9580028,76013,804Mar 02, 2021, 05:29 PM
van Houte HansChief Financial OfficerFeb 24, 2021 Option Exercise$1.7635,41962,29735,419Feb 25, 2021, 04:18 PM
van Houte HansChief Financial OfficerFeb 24, 2021 Sale$39.9035,4191,413,2180Feb 25, 2021, 04:18 PM
van Houte HansChief Financial OfficerFeb 22, 2021 Option Exercise$1.105,3305,8865,330Feb 23, 2021, 06:04 PM
van Houte HansChief Financial OfficerFeb 22, 2021 Sale$39.935,330212,8390Feb 23, 2021, 06:04 PM
van Houte HansChief Financial OfficerFeb 18, 2021 Option Exercise$0.8413,58311,41013,583Feb 22, 2021, 04:09 PM
van Houte HansChief Financial OfficerFeb 18, 2021 Sale$35.4613,583481,62110,443Feb 22, 2021, 04:09 PM
Ring ChristineGeneral CounselFeb 18, 2021 Option Exercise$1.862,0003,7202,000Feb 22, 2021, 04:08 PM
Ring ChristineGeneral CounselFeb 18, 2021 Sale$35.882,00071,7501,600Feb 22, 2021, 04:08 PM
Hansen GwennChief Scientific OfficerFeb 18, 2021 Option Exercise$7.268005,80812,800Feb 22, 2021, 04:07 PM
Hansen GwennChief Scientific OfficerFeb 18, 2021 Sale$36.2780029,01812,200Feb 22, 2021, 04:07 PM
Beaurang PierreChief Business OfficerFeb 18, 2021 Option Exercise$3.6815,00055,27515,000Feb 22, 2021, 04:06 PM
Beaurang PierreChief Business OfficerFeb 18, 2021 Sale$35.4915,000532,35212,353Feb 22, 2021, 04:06 PM
Hansen GwennChief Scientific OfficerNov 30, 2020 Option Exercise$0.8412,00010,08012,000Dec 01, 2020, 09:32 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
van Houte HansChief Financial Officer05/02/202444,878
van Houte HansChief Financial Officer04/30/202416,703
Hansen GwennChief Scientific Officer04/30/202424,169
Ring ChristineChief Legal Officer04/30/202418,220
van Houte HansChief Financial Officer02/16/202468,223
van Houte HansChief Financial Officer01/30/202413,352
Hansen GwennChief Scientific Officer01/30/202418,649
Ring ChristineChief Legal Officer01/30/202414,063
van Houte HansChief Financial Officer12/20/202335,421
van Houte HansChief Financial Officer12/19/2023109,093
van Houte HansChief Financial Officer10/31/20235,613
Ring ChristineChief Legal Officer10/31/20236,403
Hansen GwennChief Scientific Officer10/31/20238,487
van Houte HansChief Financial Officer07/31/202312,020
Ring ChristineGeneral Counsel07/31/202313,710
Hansen GwennChief Scientific Officer07/31/202318,189
Wolff StefaniEVP and COO05/01/20233,378
van Houte HansChief Financial Officer05/01/20237,121
Ring ChristineGeneral Counsel05/01/20236,736
Hansen GwennChief Scientific Officer05/01/202311,219
Wolff StefaniEVP and COO01/30/20234,995
van Houte HansChief Financial Officer01/30/202310,884
Ring ChristineGeneral Counsel01/30/20239,989
Hansen GwennChief Scientific Officer01/30/202316,633
van Houte HansChief Financial Officer10/31/20229,519
Ring ChristineGeneral Counsel10/31/20229,003
Hansen GwennChief Scientific Officer10/31/202215,006
Wolff StefaniEVP and COO10/31/20224,508
Ring ChristineGeneral Counsel08/01/202211,157
Wolff StefaniEVP and COO08/01/20225,579
van Houte HansChief Financial Officer08/01/202211,784
Hansen GwennChief Scientific Officer08/01/202218,585
van Houte HansChief Financial Officer05/31/202257,400
Hansen GwennChief Scientific Officer05/02/202212,902
Wolff StefaniEVP and COO05/02/20223,878
van Houte HansChief Financial Officer05/02/20228,190
Ring ChristineGeneral Counsel05/02/20227,755
Ring ChristineGeneral Counsel01/10/20222,232
Ring ChristineGeneral Counsel01/10/202232,568
Ring ChristineGeneral Counsel12/10/20212,232
Ring ChristineGeneral Counsel12/10/202134,848
Hansen GwennChief Scientific Officer12/01/20212,904
Hansen GwennChief Scientific Officer12/01/202111,652
Ring ChristineGeneral Counsel11/10/20212,232
Ring ChristineGeneral Counsel11/10/202138,856
Hansen GwennChief Scientific Officer11/01/20212,904
Hansen GwennChief Scientific Officer11/01/202113,296
Ring ChristineGeneral Counsel10/27/20211,488
Ring ChristineGeneral Counsel10/27/202128,200
Hansen GwennChief Scientific Officer10/27/20212,904
Hansen GwennChief Scientific Officer10/27/202114,000
Ring ChristineGeneral Counsel10/11/20212,232
Ring ChristineGeneral Counsel10/11/202132,832
Hansen GwennChief Scientific Officer10/01/20212,904
Hansen GwennChief Scientific Officer10/01/202111,968
Ring ChristineGeneral Counsel09/10/20213,720
Ring ChristineGeneral Counsel09/10/202171,860
Ring ChristineGeneral Counsel09/07/20215,952
Ring ChristineGeneral Counsel09/07/2021112,800
Hansen GwennChief Scientific Officer09/07/202111,616
Hansen GwennChief Scientific Officer09/07/202156,000
Hansen GwennChief Scientific Officer09/01/20212,904
Hansen GwennChief Scientific Officer09/01/202112,936
Ring ChristineGeneral Counsel08/10/20212,232
Ring ChristineGeneral Counsel08/10/202135,845
Beaurang PierreChief Business Officer08/10/20218,325
Beaurang PierreChief Business Officer08/10/2021223,926
Hansen GwennChief Scientific Officer08/02/20212,904
Hansen GwennChief Scientific Officer08/02/202112,484
Ring ChristineGeneral Counsel07/20/20212,232
Ring ChristineGeneral Counsel07/20/202132,400
Beaurang PierreChief Business Officer07/12/20218,325
Beaurang PierreChief Business Officer07/12/2021179,419
Hansen GwennChief Scientific Officer07/01/20212,904
Hansen GwennChief Scientific Officer07/01/202110,704
Ring ChristineGeneral Counsel05/10/20212,232
Ring ChristineGeneral Counsel05/10/202132,400
Ring ChristineGeneral Counsel04/28/20211,488
Ring ChristineGeneral Counsel04/28/202128,200
Ring ChristineGeneral Counsel04/12/20212,232
Ring ChristineGeneral Counsel04/12/202132,640
Beaurang PierreChief Business Officer04/12/20217,678
Beaurang PierreChief Business Officer04/12/2021204,632
Beaurang PierreChief Business Officer03/25/20213,637
Hansen GwennChief Scientific Officer03/16/20215,808
Hansen GwennChief Scientific Officer03/16/202136,000
Ring ChristineGeneral Counsel03/10/20213,720
Ring ChristineGeneral Counsel03/10/202182,539
Beaurang PierreChief Business Officer03/08/20216,300
Beaurang PierreChief Business Officer03/08/2021277,678
Hansen GwennChief Scientific Officer03/01/20215,808
Hansen GwennChief Scientific Officer03/01/202128,760
van Houte HansChief Financial Officer02/24/202162,297
van Houte HansChief Financial Officer02/24/20211,413,218
van Houte HansChief Financial Officer02/22/20215,886
van Houte HansChief Financial Officer02/22/2021212,839
van Houte HansChief Financial Officer02/18/202111,410
van Houte HansChief Financial Officer02/18/2021481,621
Ring ChristineGeneral Counsel02/18/20213,720
Ring ChristineGeneral Counsel02/18/202171,750
Hansen GwennChief Scientific Officer02/18/20215,808
Hansen GwennChief Scientific Officer02/18/202129,018
Beaurang PierreChief Business Officer02/18/202155,275
Beaurang PierreChief Business Officer02/18/2021532,352
Hansen GwennChief Scientific Officer11/30/202010,080
Load More Insider Transactions
FUNDS WITH A POSITION IN NURIX THERAPEUTICS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.4,580,4140.00157%-1.36%Other
BAKER BROS. ADVISORS LP3,882,1250.72%No changeOther
ARK INVESTMENT MANAGEMENT LLC2,635,3380.27%-17.52%Growth
GEODE CAPITAL MANAGEMENT, LLC1,100,3350.0015%1.83%Other
CANDRIAM S.C.A.892,1100.08%-2.83%Other
RENAISSANCE TECHNOLOGIES LLC179,3000.00414%55.64%Other
DUQUESNE FAMILY OFFICE LLC44,2000.01%NewOther
AQR CAPITAL MANAGEMENT LLC12,0420.0003%-56.14%Other
BLACKSTONE INC.27,1190.00161%No changeOther
BALYASNY ASSET MANAGEMENT L.P.22,5810.00044%ExitedEvent Driven
TUDOR INVESTMENT CORP ET AL22,0710.00183%ExitedEvent Driven, Other
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)16,5170.00422%5.08%Other
CHANGE IN SHARES OUTSTANDING FOR NURIX THERAPEUTICS INC
STOCK BUYBACKS FOR NURIX THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
02/29/2024
11/30/2023
0.43%
1Q
02/29/2024
08/31/2023
0.94%
2Q
02/29/2024
05/31/2023
1.19%
3Q
02/29/2024
02/28/2023
1.62%
4Q
02/29/2024
11/30/2022
1.82%
5Q
02/29/2024
08/31/2022
7.93%
6Q
02/29/2024
05/31/2022
22.28%
7Q
02/29/2024
02/28/2022
22.84%
8Q
02/29/2024
11/30/2021
23.24%
9Q
02/29/2024
08/31/2021
23.73%
10Q
02/29/2024
05/31/2021
25.34%
11Q
02/29/2024
02/28/2021
41.59%
12Q
Load More

Period of Report: 02/29/2024

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
11/30/2023
0.43%
1Q
08/31/2023
0.94%
2Q
05/31/2023
1.19%
3Q
02/28/2023
1.62%
4Q
11/30/2022
1.82%
5Q
08/31/2022
7.93%
6Q
05/31/2022
22.28%
7Q
02/28/2022
22.84%
8Q
11/30/2021
23.24%
9Q
08/31/2021
23.73%
10Q
05/31/2021
25.34%
11Q
02/28/2021
41.59%
12Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR NURIX THERAPEUTICS INC
LOADING...